Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $14.17M rose 48.1% year over year, ahead of the +35.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.8% from the prior quarter. Over 3 fiscal years it compounded at +74.2% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +48.1% holds above the trailing-twelve-month pace of +35.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$14.17M+4.8% QoQ
Last fiscal yearDec 2025
$37.61M-16.1% YoY
LTMSep 2026
$50.3M+35.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.1%——
1 year-16.1%——
3-year CAGR+74.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
37.61M USD
Year-over-year change
-16.1%
4-year CAGR
+47.1%

Stock-Based Compensation vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +35.9% is the 3rd highest of 8, against a peer median of +21.9%.
  • Stock-based compensation amounts to 55.6% of revenue for SYRE, versus a peer median of 144.0%.
SYRE Competitors
Stock-Based Compensation for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$51.03M USD+21.9%+65.8%11.9%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$50.3M USD+35.9%+74.2%55.6%
ANABAnaptysBio, Inc.LTM Mar 2026$41.12M USD+24.3%+9.7%17.7%
UPBUpstream Bio, Inc.LTM Mar 2026$12.34M USD+54.4%+100.6%371.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M USD-2.1%-6.3%144.0%
IMUXImmunic, Inc.LTM Mar 2026$11.29M USD+44.4%+3.8%—
IFRXInflaRx N.V.LTM Mar 2026€2.48M EUR-152.9%—8455.2%
ABVXAbivax S.A.FY2025€0 EUR-100.0%——
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding SYRE) —+21.9%+9.7%144.0%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Depreciation & Amortization1.58M1.96M744K010M
Deferred Income Tax0(327K)000
Stock-Based Compensation8.04M7.11M25.68M44.83M37.61M
Change in Working Capital1.83M(5.5M)(5.21M)(4.53M)(5.93M)
Accounts Receivables(815K)440K375K00
Inventory0(440K)000
Accounts Payables1.07M(2.64M)218K(230K)7.65M
Other Working Capital1.58M(2.86M)(5.8M)(4.3M)(13.58M)
Other Non-Cash Items638K426K217.67M10.31M(55.73M)
Operating Cash Flow(53.72M)(80.14M)(99.91M)(157.41M)(169.25M)
Capital Expenditures(573K)(38K)000
Acquisitions (Net)003.04M00
Purchases of Investments(133.08M)(39.5M)(166.8M)(599.25M)(522.21M)
Sales of Investments111.03M96.55M39.9M245.97M371.74M
Other Investing Activities0015.48M07M
Investing Cash Flow(22.62M)57.01M(108.39M)(353.29M)(143.48M)
Debt Repayment(510K)(418K)(16K)00
Common Stock Issued042.87M169.11M236.38M314.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.9M222K(5.38M)5.67M(5.41M)
Financing Cash Flow1.39M42.68M361.08M410.91M309.03M
Effect of Forex Changes(15K)(106K)25K(3K)0
Net Change in Cash(74.96M)19.44M152.8M(99.79M)(3.7M)
Free Cash Flow(54.29M)(80.18M)(99.91M)(157.41M)(169.25M)

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.